34 completed, 18 recruiting, 16 terminated, 10 active not recruiting. 87 Phase 2, 30 Phase 1, 1 Phase 3.
Follow azacytidine: new trials by email Literature Review of azacytidine trials Research Report on azacytidine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial) Azacitidine, Bone Marrow Aspiration and Biopsy, Cytarabine - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 184 | 2027-01-04 | 2026-10-01 |
| Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) azacytidine, carboplatin, paclitaxel - Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 60 | 2026-11-02 | 2026-10-28 |
| Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms Pacritinib, Decitabine, Decitabine and Cedazuridine - Accelerated Phase Myeloproliferative Neoplasm, Blast Phase Myeloproliferative Neoplasm | Phase 2 | Recruiting | University of Washington | 27 | 2026-03-02 | 2026-08-19 |
| Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent Azacitidine, Olutasidenib - Acute Myeloid Leukemia | Phase 2 | Recruiting | University of California, Davis | 28 | 2025-12-17 | 2026-10-27 |
| AZA Combined with R-GemOx for Elderly DLBCL Patients azacytidine, R-GemOx - DLBCL - Diffuse Large B Cell Lymphoma | Phase 2 | Not yet recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 80 | 2025-02-01 | 2025-01-16 |
| Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Monocytic Leukemia, Acute Myeloid Leukemia | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2025-01-03 | 2026-09-16 |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 147 | 2024-09-27 | 2026-10-28 |
| Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 335 | 2024-09-25 | 2026-10-27 |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2024-09-13 | 2026-10-28 |
| Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia Axatilimab, Azacitidine, Biospecimen Collection - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Recruiting | Uma Borate | 49 | 2024-08-02 | 2026-08-27 |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm | Phase 2 | Recruiting | National Cancer Institute (NCI) | 2000 | 2024-06-18 | 2026-10-27 |
| A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin's Lymphoma Azacytidine, Pembrolizumab - Hodgkin's Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 24 | 2022-10-05 | 2026-05-18 |
| IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study) Azacitidine, Biopsy, Enasidenib - Acute Myeloid Leukemia | Phase 2 | Recruiting | Alice Mims | 125 | 2022-09-13 | 2026-06-23 |
| Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome Azacitidine, Quality-of-Life Assessment, Questionnaire Administration - Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome | Phase 2 | Active not recruiting | Uma Borate | 33 | 2022-06-23 | 2026-05-14 |
| Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure Azacitidine, Decitabine, Venetoclax - Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia | Phase 2 | Recruiting | Brian Jonas | 20 | 2022-02-09 | 2024-05-29 |
| Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies AeroEclipse II Breath Actuated Nebulizer, Bintrafusp alfa, Azacytidine - Sarcomas, Melanomas | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2021-12-14 | 2021-12-17 | |
| Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Azacitidine, Seclidemstat - Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1 | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 24 | 2021-07-07 | 2026-09-18 |
| Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML SLS009, venetoclax, azacitidine - Hematologic Malignancies | Phase 1 / Phase 2 | Recruiting | Sellas Life Sciences Group | 160 | 2021-05-10 | 2026-09-03 |
| DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia DS-1594b, Azacitidine, Cyclophosphamide - Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 17 | 2021-03-25 | 2025-05-23 |
Showing 20 of 87. Sign in to see all of them.
Leukemia, Myeloid, Acute (48) · Myelodysplastic Syndromes (30) · Leukemia, Myelomonocytic, Chronic (21) · Leukemia (11) · Myeloproliferative Disorders (8) · Carcinoma, Non-Small-Cell Lung (5) · Leukemia, Biphenotypic, Acute (5) · Leukemia, Erythroblastic, Acute (5) · Leukemia, Megakaryoblastic, Acute (5) · Leukemia, Monocytic, Acute (5) · Leukemia, Myelomonocytic, Acute (5) · Anemia, Refractory, with Excess of Blasts (4) · Congenital Abnormalities (3) · Lymphoma (3) · Lymphoma, Large B-Cell, Diffuse (3)
M.D. Anderson Cancer Center (36) · National Cancer Institute (NCI) (25) · Fred Hutchinson Cancer Center (3) · Uma Borate (2) · Weill Medical College of Cornell University (2) · Alice Mims (1) · Arog Pharmaceuticals, Inc. (1) · Brenda Cooper, MD (1) · Brian Jonas (1) · Carlos Graux, MD, PhD (1) · Case Comprehensive Cancer Center (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · King Fahad Medical City (1) · OHSU Knight Cancer Institute (1) · Rutgers, The State University of New Jersey (1)
United States (78) · Canada (6) · Puerto Rico (5) · China (2) · Australia (1) · Belgium (1) · Italy (1) · Saudi Arabia (1) · Switzerland (1)
Guillermo Garcia-Manero (5) · Courtney DiNardo (3) · Naval Daver (3) · Nicholas Short (3) · Bart Scott (2) · Brian A Jonas (2) · Courtney DiNardo, MD (2) · David S Schrump, M.D. (2) · Guillermo Garcia-Manero, MD (2) · Guillermo M Bravo (2) · Naval Daver, MD (2) · Naval G Daver (2) · Peter Martin, MD (2) · Tapan M Kadia (2) · Uma M Borate, MD (2)
PMID 24583822, PMID 18042004, PMID 22586682, PMID 23265768, PMID 23547838, PMID 24092933, PMID 24142996, PMID 26577691, PMID 29134664, PMID 29618479, PMID 30001986, PMID 30028037, PMID 30185431, PMID 31212080, PMID 34889407, PMID 34980577, PMID 35078972, PMID 35442137, PMID 35704787, PMID 35973199, PMID 36063832, PMID 36841758, PMID 36902217, PMID 37422688, PMID 38277619, PMID 38391202, PMID 38548404, PMID 38744144, PMID 38867582, PMID 39300320, PMID 40073835, PMID 40513054, PMID 40932107, PMID 42035228, PMID 42200455, PMID 42304430
P30CA006973 (4), U10CA180820 (4), U10CA180888 (4), P30CA016672 (3), N01CM00038 (2), N01CM00099 (2), P30CA015704 (2), P30CA093373 (2), U01CA070095 (2), U10CA032102 (2), UM1CA186691 (2), N01CM00070 (1), N01CM17103 (1), N01CM62204 (1), N01CM62205 (1)